[
  {
    "ticker": "MPP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964021",
    "id": "02964021",
    "pages": 2,
    "price_sensitive": true,
    "date": "20250701",
    "time": "0731",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l9932r1ktnvl.pdf",
    "summary": "<ul>\n<li><strong>Capital Raising Structure</strong>: Combination of renounceable rights issue ($9m) and placement to new cornerstone investor Amari Metals ($6m min, $15m-$24m total raise).  </li>\n<li><strong>Pricing</strong>: 3c per share.  </li>\n<li><strong>Ownership Post-Raising</strong>: Amari to hold 51.0%.  </li>\n<li><strong>Conditions</strong>: Shareholder approval required (meeting expected late August 2025). Cross-completion with new loan facility.  </li>\n<li><strong>New Loan Facility</strong>: 3-year term, same pricing as current facility. Current facilities extended to 30 September 2025.  </li>\n<li><strong>Timetable</strong>: Offer documentation expected early August 2025.  </li>\n</ul>\n<p>(<em>Omitted: Director names, investor background, operational commentary as non-material to capital structure/trading decisions.</em>)</p>",
    "usage": {
      "prompt_tokens": 1159,
      "completion_tokens": 168,
      "total_tokens": 1327,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:54:12.077125"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964020",
    "id": "02964020",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0731",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l990zgn71gvv.pdf",
    "summary": "<h3>Summary of ASX Announcement: Quarterly Update (Appendix 4C Equivalent)</h3>\n<h4><strong>Key Highlights</strong></h4>\n<ul>\n<li><strong>Combogesic IV (Maxigesic IV) launch in Canada</strong> begins this month, targeting opioid alternatives in pain management.  </li>\n<li><strong>US licensing agreement with Hikma Pharmaceuticals extended</strong>: Restructured profit-sharing for Combogesic IV/Rapid; Hikma to oversee all US channels (excluding Alexso\u2019s niche markets).  </li>\n<li><strong>R&amp;D progress</strong>:  </li>\n<li>Pre-IND filed for antibiotic eyedrop (targeting resistant infections); IND filing planned pre-year-end.  </li>\n<li>Pre-IND upcoming for Strawberry Birthmarks topical; IND for novel iron injection by year-end.  </li>\n<li>New formulation project added (targeting ~US$180M niche market).  </li>\n<li><strong>Pediatric expansion</strong>: Maxigesic IV study for pediatric use planned to broaden market.  </li>\n<li><strong>Commercial pipeline</strong>: Five out-licensing deals completed; more in negotiation.  </li>\n</ul>\n<h4><strong>Strategic Impact</strong></h4>\n<ul>\n<li>Expands North American footprint (Canada launch, US partnership restructuring).  </li>\n<li>Advances high-potential R&amp;D assets with near-term regulatory milestones.  </li>\n</ul>\n<p><strong>No material financial data (e.g., cash balance) disclosed.</strong>  </p>\n<p><em>(Note: Omitted operational, market context, and non-material details.)</em></p>",
    "usage": {
      "prompt_tokens": 2426,
      "completion_tokens": 274,
      "total_tokens": 2700,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:54:46.334533"
  },
  {
    "ticker": "AIA",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964018",
    "id": "02964018",
    "pages": 1,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l98wrcx6pw71.pdf",
    "summary": "<p>Understood. Please upload or provide the text of the ASX announcement PDF you'd like analyzed, and I will extract the material information in the prescribed format, tailored to the announcement type. </p>\n<p>For example, if you provide:<br />\n- A <strong>trading halt request</strong>, I'll state only the reason.<br />\n- A <strong>capital raising</strong>, I'll list structure, amount, and key dates.<br />\n- A <strong>quarterly (4C)</strong>, I'll note operational/financial highlights and cash balance.<br />\n- Other types, I'll distill the 2-3 most critical points impacting valuation or liquidity.  </p>\n<p>I\u2019ll omit all fluff, names, and non-material details. If the document lacks actionable info, I\u2019ll note: <em>No material information identified</em>.  </p>\n<p>Go ahead and share the announcement.</p>",
    "usage": {
      "prompt_tokens": 218,
      "completion_tokens": 167,
      "total_tokens": 385,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:53:51.183312"
  },
  {
    "ticker": "CNU",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964019",
    "id": "02964019",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l98yw68lrr7b.pdf",
    "summary": "<ul>\n<li><strong>Redemption of Crown Funding Securities</strong>:  </li>\n<li>85,341,018 unquoted CIP1 equity securities redeemed at NZ$1.00 each (total NZD 85.3M).  </li>\n<li>7,561,881 unquoted CIP1 warrants cancelled at nil consideration.  </li>\n<li>Repayment of NZD 85.3M unquoted CIP1 debt securities.  </li>\n<li><strong>Impact on Capital Structure</strong>:  </li>\n<li>Redemption reduces outstanding CIP1 equity securities to 376,711,053 (18.5% reduction).  </li>\n<li>Warrants outstanding reduced to 9,903,147 (43.3% cancellation).  </li>\n<li><strong>Reason</strong>: Dividends became payable on a portion of CIP1 equity securities, triggering redemption under pre-existing terms.  </li>\n</ul>\n<p><em>No material trading or valuation impact identified for listed securities (NZX:CNU).</em></p>",
    "usage": {
      "prompt_tokens": 1792,
      "completion_tokens": 184,
      "total_tokens": 1976,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:54:29.667591"
  },
  {
    "ticker": "IFT",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964017",
    "id": "02964017",
    "pages": 6,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l98tml9jndtl.pdf",
    "summary": "<ul>\n<li><strong>Dividend Details</strong>:  </li>\n<li><strong>Final dividend</strong>: NZD 0.1325 per share (AUD 0.1229 equivalent).  </li>\n<li><strong>Record date</strong>: 12/6/2025.  </li>\n<li><strong>Ex-date</strong>: 11/6/2025.  </li>\n<li><strong>Payment date</strong>: 2/7/2025.  </li>\n<li>\n<p><strong>Currency</strong>: NZD (withholding tax rate: 15%).  </p>\n</li>\n<li>\n<p><strong>Dividend Reinvestment Plan (DRP)</strong>:  </p>\n</li>\n<li><strong>Strike price</strong>: NZD 10.42983548 per share (2% discount applied).  </li>\n<li><strong>Election deadline</strong>: 13/6/2025.  </li>\n<li>\n<p><strong>DRP issue date</strong>: 2/7/2025.  </p>\n</li>\n<li>\n<p><strong>Key Update</strong>: Adjustment to previously announced DRP strike price (no change to dividend amount or dates).  </p>\n</li>\n</ul>\n<p><em>Omitted: FX rate details, generic DRP eligibility rules, and tax component links (non-material for immediate trading decisions).</em></p>",
    "usage": {
      "prompt_tokens": 2312,
      "completion_tokens": 217,
      "total_tokens": 2529,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:53:55.912744"
  }
]